The Ministry of Food and Drug Safety (MFDS) guidelines for new drug delivery systems in South Korea require comprehensive data on safety, efficacy, and performance. Applicants must submit preclinical and clinical data demonstrating the system’s therapeutic benefits, stability, and reliability. Compliance with Good Manufacturing Practice (GMP) standards and quality control processes is also essential for approval.
